Gubra’s value accelerator
Expand
Into new therapeutic areas and modalities where Gubra can create differentiated value
Accelerate
Lean, asset-centric companies that benefit from Gubra’s integrated capabilities
Repeat
A scalable venture engine that creates more shots on goal and multiple paths
to value
What we look for
We look for external innovation where Gubra can create differentiated value through two routes:
- by creating ventures at the discovery stage with partners bringing complementary expertise and technology; or
- by in-licensing or acquiring assets from development candidate stage onwards in areas of Gubra’s therapeutic focus
What we do
We partner with innovators to advance high-potential assets through:
- In-licensing and co-development
- Early-stage program development within the Gubra ecosystem
- A focus on translational strength and disciplined portfolio building
Our core therapeutic focus includes obesity and metabolic disease, immunology and inflammation, and functional aging.
Partner with us
We are actively seeking opportunities to collaborate on promising preclinical and early clinical programmes, as well as enabling technologies with strong translational potential.
Contact us to explore collaboration opportunities
Partner with us
Two routes in: build a company with us, or partner on an existing programme. The first conversation covers both.
Zoë Johnson
Head Gubra Ventures
Read bio
Zoë Johnson, Ph.D., Head of Ventures Zoë leads Gubra Ventures and brings more than 25 years of experience as a senior executive and board director across global pharma, venture-backed biotech and company creation. Before joining Gubra, she served as Chief Scientific and Development Officer at Molecule to Medicine, a global biotech venture builder. She previously held Chief Scientific Officer roles at Affivant (a Roivant company) and iOnctura, and senior R&D positions at UCB, Merck Serono and NovImmune. Zoë holds a Ph.D. in Pharmacology from King’s College London.
Lise Biehl Rudkjær
VP, Alliance Management
Read bio
Lise Biehl Rudkjær, Ph.D., VP, Alliance Management Lise leads alliance management at Gubra, bringing more than 15 years of experience in biotech across drug discovery, business development and alliance management. Since joining Gubra in 2016, she has led several drug discovery projects, co-negotiated several partnerships and taken on the role as alliance manager on most partnerships. Lise holds a M.Sc. in Human Biology, and a Ph.D. from the Biotech Research & Innovation Centre (BRIC), University of Copenhagen.
Jacob Lange Moresco
VP, Business Development & Partnerships
Read bio
Jacob Lange Moresco, Ph.D., VP, Business Development & Partnerships Jacob leads business development and partnerships at Gubra, having joined in 2025 after 15 years in venture investing and pharma business development. He previously served as Investment Director at Sunstone Life Science Ventures, where he sat on the boards of Step Pharma, TargED Biopharmaceuticals and Kynexis, and earlier held business development roles at LEO Pharma. Jacob holds a Ph.D. from the Technical University of Denmark.
Andreas Schuh
Senior Vice President, Venture Partner
Read bio
Andreas Schuh, Senior Vice President, Venture Partner Andreas joined Gubra in October 2026 as Venture Partner. He brings extensive finance and operations leadership experience across the pharmaceutical, biotechnology and medical device sectors. Most recently, he served as CFO at Quercis Pharma and Opterion Health, and as CFO and COO at Nuclidium. Previously, he held executive finance roles at Roivant and served as interim CFO at Advesya, a Jeito-backed company. During more than seven years at Novartis, he held senior finance positions, including VP Finance for Global Drug Development, VP Finance for Productivity & Margin Improvement, and Head of Finance for the Worldwide Respiratory Franchise. Earlier in his career, he worked at Deloitte and KPMG.
Andreas holds a Master’s degree from the Vienna University of Economics and Business Administration.
We measure our success by the value we create for our customers. Our role is to turn complex research questions into clear insights that help select promising drug candidates and move development forward quickly”
Zoë Johnson
Head Gubra Ventures
EVENTS CALENDAR for Ventures
Meet us here
BIO Europe Autumn 26 in Cologne
Meet Gubra at the Bio Europe Autumn conference i Cologne November 9-11 2026. Georg Duenstl and Jacob Lange Moresco from Gubra will be there.
The 32nd edition of BIO-Europe takes place at Koelnmesse and brings together leaders from biotech, pharma and investment for partnering meetings and a programme covering regulatory, clinical and manufacturing strategy.
Drug Discovery Chemistry Europe 2026
Gubra will attend Drug Discovery Chemistry Europe 2026 on November 10–12, 2026 in Barcelona, Spain.
Drug Discovery Chemistry Europe is organised by Cambridge Healthtech Institute (CHI) and takes place at the InterContinental Barcelona. The programme covers lead generation, AI and machine learning in drug discovery, next-generation protein degraders and protein-protein interactions, including small molecules and peptides that target them.
CBMR Innovation Summit on Cardiometabolic Health in Copenhagen
Gubra is attending the CBMR innovation Summit and Markus Rohrwild, CEO of Gubra will speak Nov 12th on “From discovery to differentiated medicines: Gubra’s unique business model for continuous innovation.
The summit is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, at Comwell Copenhagen Portside in Nordhavn. Over three days, leaders from academia, biotech, pharma and healthcare meet for keynotes, talks and panel debates on the next generation of prevention and treatment for cardiometabolic disease.
Gubra world offices
Hørsholm
Hørsholm Kongevej 11B, 2970 Denmark
Basel
Rudolf Geigy-Strasse 3, Allschwil
Boston
CIC, 1 Broadway, Cambridge, MA
For further information